Market access is about aligning internal strategies with external realities that often change without warning and at a frequency likely not experienced by other biopharma executive roles.

AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase of growth and efficiency in specialty pharmacy.

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Brett Casper explores the marketplace complexities that manufacturers face regularly.

The German company will expand its access into the United States through the acquisition.

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global pharmaceutical company.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with chronic and rare conditions.

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping life sciences companies deliver therapies more efficiently to patients.

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

The emerging biotech scene in Chicago has the potential to develop new treatments and technologies, but funding cuts from the federal government could have significant impact on this.

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

Arda Ural discusses the possible impact on how companies plan for growth based on the impact of the tariffs.

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced nasopharyngeal carcinoma.

The company will be adding a new manufacturing site to its NJ campus for the drug Adstiladrin.

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.

Arda Ural discusses the different ways that companies may change the ways they allocate resources in the current geopolitical climate.

A new study shows that varenicline combined with brief remote counseling significantly improves vaping abstinence in in patients between 16 and 25 years of age.

The submission is backed by clinical data from over 2,100 patients, including two pivotal Phase III trials in patients treated with trenibotulinumtoxinE for moderate to severe glabellar lines.

Lynlee Brown, partner at EY, discusses the impacts that the tariffs have across various regions.

Chris Springate, CEO, ARC Medical, discusses how postoperative adhesions continue to cause chronic pain, infertility, and life-threatening complications—despite advances in surgical techniques and often going undiagnosed for years.